tbuckley/cabot-search huggingface dataset:
Haploidentical‐ versus identical‐sibling transplant for high‐risk pediatric AML: A multi‐center study
Authors: Feng-Mei Zheng, Xi Zhang, Chun-Fu Li, Yi-Fei Cheng, Li Gao, Yue-Lin He, Yu Wang, Xiao-Jun Huang
Journal: Cancer Communications (2020)

Abstract Background Human leukocyte antigen‐identical sibling donor (ISD)‐hematopoietic stem cell transplantation (SCT) is a potentially curative treatment for high‐risk pediatric acute myeloid leukemia (AML). A haploidentical donor (HID) is readily available to almost all children. Previous studies have demonstrated that patients with HID‐SCT had similar outcomes compared to ISD‐SCT for pediatric and adult AML. However, the role of HID‐SCT in high‐risk pediatric AML is unclear. Methods To compare the overall survival of high‐risk AML children who underwent either HID‐SCT or ISD‐SCT, we analyzed 179 cases of high‐risk AML patients under 18 years of age treated with either ISD‐SCT ( n = 23) or HID‐SCT ( n = 156). Granulocyte colony‐stimulating factor plus anti‐thymocyte globulin‐based regimens were used for HID‐SCT. We also analyzed the subgroup data of AML patients at first complete remission (CR1) before SCT with known cytogenetic risk. Results The numbers of adverse cytogenetic risk recipients were 8 (34.8%) and 13 (18.8%) in the ISD‐SCT group and the HID‐SCT group, and the number of patients with disease status beyond CR1 were 6 (26.1%) and 14 (20.3%) in the two groups. The cumulative rates of grades II‐IV acute graft‐versus‐host disease (GVHD) were 13.0% in the ISD‐SCT group and 34.8% in the HID‐SCT group ( P = 0.062), with a three‐year cumulative rates of chronic GVHD at 14.1% and 34.9%, respectively ( P = 0.091). The relapse rate in the ISD‐SCT group was significantly higher than that in the HID‐SCT group (39.1% vs. 16.4%, P = 0.027); with non‐relapse mortality at 0.0% and 10.6% ( P = 0.113), respectively. The three‐year overall survival rates were 73.0% for the ISD‐SCT group and 74.6% for the HID‐SCT group ( P = 0.689). In subgroup analysis, the three‐year relapse rate in the ISD‐SCT group was higher than that in the HID‐SCT group (50.0% vs. 9.2%, P = 0.001) and the three‐year DFS in the ISD‐SCT group (50.0%) was lower than that in the HID‐SCT group (81.2%) ( P = 0.021). Conclusions Unmanipulated HID‐SCT achieved DFS and OS outcomes comparable to those of ISD‐SCT for high‐risk pediatric AML patients with potentially higher rate but manageable GVHD.
EARLY READMISSION DUE TO RECURRENT ATRIAL ARRHYTHMIA AFTER ATRIAL FIBRILLATION ABLATION: AN OVERLOOKED COMPLICATION
Authors: Lingling Wu, Bharat Narasimhan, Faris Haddadin, Kam Ho, Yingying Zheng, Bharat Kantharia
Journal: Journal of the American College of Cardiology (2020)
INCREASED RISK OF ADVERSE CARDIOVASCULAR EVENTS ASSOCIATED WITH IBRUTINIB USE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A PROPENSITY-MATCHED POPULATION-BASED COHORT STUDY
Authors: Nasruddin Sabrie, Darryl Leong, Anca Prica, Peter Austin, Andrea Pang, Jiming Fang, Oscar Calvillo-Arguelles, Douglas Lee, Paaladinesh Thavendiranathan, Husam Abdel-Qadir
Journal: Journal of the American College of Cardiology (2020)
High-risk uveal melanoma: A prospective study evaluating the role of magnetic resonance imaging of the liver.
Authors: Ernest Marshall, Chris Romaniuk, Paula Ghaneh, Helen Wong, Marie McKay, Mona Chopra, Sarah Coupland, Bertil Damato
Journal: Journal of Clinical Oncology (2012)

8564 Background: Almost 50% of uveal melanomas are fatal. Metastatic death occurs almost exclusively with tumours showing chromosome 3 loss and 8q gain. Metastases, which almost always involve the liver, are resectable in some patients. They are rarely detectable when the patient presents with the primary ocular tumour. Screening is therefore necessary, but there is no consensus as to who should be screened, how often, and for how long. Methods: Uveal melanoma patients with ECOG performance status 0-2 were eligible if their risk of metastatic death at 5 years exceeded 50%. Survival probability was estimated by multivariate analysis of tumour stage, histological grade and genetic tumour type. Patients underwent screening 6monthly, clinical examination, non-contrast liver MRI and liver function tests for at least five years. Results: Between Jan 2000 and November 2010, 279 high-risk patients were referred for screening. Of these, 188 (84 male, 104 female) accepted screening and underwent as least 1 MRI. The median age was 63 years (IQR 16.5). Median basal tumour diameter was 16.5mm (IQR 5.25). Chromosome 3 loss was detected in 175 tumours. Median follow up time was 28.8 months (IQR 29.1). Median relapse-free survival was 33 months (95% CI 28-38) with a 35% relapse-free survival at 5 years. After a median of 18 months (IQR 20), screening detected metastases in 90/188 (48%), 83 of whom were asymptomatic. 12 patients underwent R0 liver resection, which increased the median survival from 10 (95% CI 8.1 - 11.9) to 24 (95% CI 20.2- 27.8) months. The screening programme stimulated a UK NCRI portfolio of clinical trials in which 23 of these patients were subsequently treated. Conclusions: Six-monthly liver MRI detects metastases from uveal melanoma at an early stage, thereby enhancing opportunities for surgical metastatectomy, clinical trial participation and prolonging life.
Adjuvant 131I-metuximab for hepatocellular carcinoma after liver resection: a randomised, controlled, multicentre, open-label, phase 2 trial
Authors: Jun Li, Jingliang Xing, Yefa Yang, Jingfeng Liu, Wentao Wang, Yong Xia, Zhenlin Yan, Kui Wang, Dong Wu, Lu Wu, Xuying Wan, Tian Yang, Chunfang Gao, Anfeng Si, Hongyang Wang, Mengchao Wu, Wan Yee Lau, Zhinan Chen, Feng Shen
Journal: The Lancet. Gastroenterology & hepatology (2020)
THE EFFICACY OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR (ICD) FOR PRIMARY PREVENTION OF SUDDEN CARDIAC DEATH (SCD) IN PATIENTS WITH HEART FAILURE (HF) WITH EJECTION FRACTION (EF) 35 PERCENT OR LESS IS NOT AFFECTED BY THE METHOD USED TO ESTIMATE THE EF: INSIGHTS FROM THE SUDDEN CARDIAC DEATH IN HEART FAILURE TRIAL (SCD-HEFT)
Authors: Hilda Mariana Gonzalez Bonilla, Nitheesha Ganta, Michael Greenberg, Phillip Hong Lam, Ami E. Iskandrian, Jason Morrissette, Erin Goheen-Thomas, Steve Singh, Ali Ahmed
Journal: Journal of the American College of Cardiology (2020)
The effect of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Authors: Halit Karaca, Veli Berk, Mevlude Inanc, Mustafa Dikilitas, Metin Ozkan
Journal: Journal of Clinical Oncology (2013)

e20603 Background: β-glucans have antibacterial, immunomodulator and anti-cancer effects. The present study aimed to determine the effect of oral β-glucan on mucositis and leukopenia in a group of colorectal cancer patients with a high risk for neutropenia and mucositis who received adjuvant FOLFOX-4 (oxaliplatin, 5-flourouracil, and folinic acid) combination chemotherapy. Methods: This retrospective study included 62 patients with colorectal cancer that underwent a FOLFOX-4 treatment regimen between July 2009 and July 2010. Ethics committee of Erciyes University approved the study design. Colorectal cancer patients treated with a FOLFOX-4 regimen were retrospectively evaluated in 2 equal groups: One group received β-glucan (treatment group), and the other did not (control group). In both groups the level of leucocytes, neutrophils, and platelets were evaluated before and 1 week after chemotherapy. The occurrence of oral mucositis and diarrhea was noted. Data were statistically analyzed. Results: There were 21 male and 10 female patients in the treatment group, and the median age was 61 years (range: 43-72 years). The control group included 17 male and 14 female patients, and the median age was 55 years (range: 30-78 years). There weren't any statistically differences in age or gender between the 2 groups. Leucocyte and neutrophil counts after chemotherapy in the treatment group were 7300/mm 3 and 3800/mm 3 , respectively, and the reductions, as compared to baseline, were not significant (p = 0.673 and 0.784). The median platelet count was 264000/mm 3 after chemotherapy in the treatment group and the reduction, as compared to baseline, was borderline significant (p = 0.048). In the control group the reduction in leucocyte, neutrophil, and platelet counts was statistically significant (median values were 5600/mm 3 , 2880/mm 3 , and 229000/mm 3 , respectively; p &lt; 0.01). In addition, oral mucositis and diarrhea secondary to chemotherapy were less common in the treatment group (19% v.s 42%). Conclusions: β-glucan effectively suppressed the adverse effects of chemotherapy. We think that nutritional supplementation with β-glucan in cancer patients should be investigated further.
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
Authors: Daniel J Olson, Padma Rajagopal, Melissa Y Tjota, Girish Venkataraman, Jason J Luke, Thomas F Gajewski
Journal: Journal for ImmunoTherapy of Cancer (2020)

Background The combination of the immune checkpoint inhibitors (ICIs) ipilimumab and nivolumab is a mainstay of treatment for selected patients with metastatic melanoma. This combination also results in more frequent immune-related adverse events (irAEs) than either ICI alone. These irAEs can be severe and their pathogenesis is poorly understood. Case presentation We report a case of a woman with metastatic melanoma, treated with combined ipilimumab and nivolumab, who developed severe anaemia. While initial workup revealed autoimmune haemolytic anaemia, the anaemia persisted despite corticosteroids and paradoxical reticulocytopenia was observed. Bone marrow biopsy demonstrated a CD8 + T cell-mediated destruction of the red cell precursors implying concurrent pure red cell aplasia. Both processes resolved after the addition of cyclosporine A. Conclusions This report describes a rare case of two concurrent mechanisms of haematological irAE in a patient treated with combined ICI therapy. Successful treatment resulted only after the second underlying mechanism of toxicity was uncovered. Prompt recognition of these unusual presentations of rare irAEs is now key to effective irAE management.
BANDITS: Bayesian differential splicing accounting for sample-to-sample variability and mapping uncertainty
Authors: Simone Tiberi, Mark D. Robinson
Journal: Genome biology (2020)

Abstract Alternative splicing is a biological process during gene expression that allows a single gene to code for multiple proteins. However, splicing patterns can be altered in some conditions or diseases. Here, we present BANDITS, a R/Bioconductor package to perform differential splicing, at both gene and transcript level, based on RNA-seq data. BANDITS uses a Bayesian hierarchical structure to explicitly model the variability between samples and treats the transcript allocation of reads as latent variables. We perform an extensive benchmark across both simulated and experimental RNA-seq datasets, where BANDITS has extremely favourable performance with respect to the competitors considered.
Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients.
Authors: Giuseppe Procopio, Elena Verzoni, Roberto Iacovelli, Isabella Testa, Roberto Salvioni, Nicola Nicolai, Luca Porcu, Filippo G. De Braud
Journal: Journal of Clinical Oncology (2012)

4629 Background: Targeted Therapies (TTs) have definitely improved survival in patients with mRCC. However the optimal therapeutic strategy is not shared. This study was performed to assess the overall survival (OS) in a consecutive series of mRCC patients receiving TTs. Methods: Characteristics and outcomes of 336 patients affected by mRCC receiving TTs were collected from the database of Istituto Nazionale Tumori of Milan. The main characteristics of patients were: ECOG PS 0/1/2 186 (55%)/131 (39%)/19 (6 %); clear-cell histology 291 (87%); previous nephrectomy 293 (87%). According to Motzer criteria 32% of patients showed low risk, 48% intermediate risk and 20% poor. Overall, 167 (50%) patients received one TTs, while 116 (34%), 42 (13%) and 11 (3.3%) received 2, 3 and 4 TTs, respectively. 245 (73%) patients received sorafenib (So), 212 (63%) sunitinib (Su), 33 (10%) a bevacizumab regimen and 73 (22%) other TTs, including everolimus, temsirolimus and axitinib. The Kaplan Meier curves were used to describe the survival.The uni- and multi-variate analyses for OS were carried out by means of Cox proportional hazard regression analysis. Results: Ata median follow-up of 43 months, 199 patients (57 %) had died. The median OS was 24 months (95%CI: 20.0-27.0) and the 5-year OS was 24.6 % (95 %CI: 18.7-30.8). In univariate analyses, there were no significant differences in the hazard ratios (HR) for So followed by Su compared to Su followed by So (HR SU- SO / SO- SU = 1.16; 95%CI: 0.57-2.33) or compared with other therapies (HR Other sequential th. / SO- SU = 1.21; 95%CI: 0.78-1.88; p=0.674).In the multivariate analysis, in terms of OS any statistical difference was reported as regards the sequence used (Su/So vs So/Su; p&gt;0.05) or bevacizumab regimen as compared to Su and/or So used sequentially (p&gt;0.05). In the uni and multivariate analysis ECOG PS, nephrectomy, Fuhrman grade and number of sites of disease are independent predictive factors of outcome (p&lt; 0.01). Conclusions: These data suggest that TTs improve OS in mRCC without any statistical difference when using different sequences of TTs. No cross-resistance between several sequences of TTs was documented.
COMPARISON OF CLINICAL SAFETY AND EFFICACY BETWEEN SAPIEN 3 20MM AND UNDERFILLED 23MM IN PATIENTS WITH A SMALL ANATOMY
Authors: Go Hiasa, Hideki Okayama, Shunsuke Kido, Aono Tetsuya, Matsuda Kensho, Yuta Tanaka, Tetsuya Kosaki, Saki Hosokawa, Go Kawamura, Tatsuya Shigematsu, Yoshitaka Kawada, Tadakatsu Yamada, Yukio Kazatani
Journal: Journal of the American College of Cardiology (2020)
GERIATRIC PATIENTS WITH PREDIABETES MAY HAVE UPTO 33% GREATER RISK OF STROKE WITH CONCOMITANT ALCOHOL USE DISORDER
Authors: Neelesh Gupta, Rupak Desai, Alok Ravindra Amraotkar, Darshini Vora, Fariah Ash Haque, Natalie DeWitt, Zeeshan Mansuri, Kishorbhai Gangani, Rajesh Sachdeva, Gautam Kumar
Journal: Journal of the American College of Cardiology (2020)
Role of estrogen receptor-β as prognostic factor in colorectal cancer.
Authors: Lorenzo Alonso, Elisabeth Pérez-Ruiz, L. Perez-Villa, Isabel Sevilla, Esperanza Torres, V. de Luque, Martina Alvarez, Luis Vicioso, E. Alba
Journal: Journal of Clinical Oncology (2012)

e14115 Background: Gender-related differences in colorectal cancer (CRC) development have been reported with a higher incidence in males than in females and several studies suggest estrogens can be protective. The role of these receptors is controversial. The aim was to elucidate the association between estrogen receptor- β (ER- β), clinicopathological variables, disease-free survival (DFS), and overall survival (OS). Methods: Protein expression was evaluated by immunohistochemistry, and antibody staining detected in the nuclear compartment was taken into account in 109 CRC patients tissue. Results: The sample characteristics are summarized in Table 1. The expression of nuclear ERβ was found to be positive in 101 cases (92.7%), and only 8 cases (7.3%) were negative. The ERβ expression was found to be associated with mucinous histology (p&lt;0.0001), while no association was found with any of the remaining variables examined. There was a non significant association between ERβ and IIIB-IV stage. Median follow-up was 38 months and there was no correlation with the clinical outcome and ERβ status. Conclusions: In our small sample, it appears that ERβ did not influence the clinical outcome although the number of events is too small to draw conclusions. We have described an association between negative ERβ and mucinous adenocarcinoma CRC which has not been reported previously. [Table: see text]
Quantitative real time-PCR of CD133 mRNA: A potential surrogate angiogenic marker of response for patients with metastatic sarcoma
Authors: E. H. Lin, Y. Li, J. Trent, S. M. Patel, M. A. Burgess, D. M. Steinert, R. S. Benjamin, D. Li, L. L. Chen
Journal: Journal of Clinical Oncology (2006)

20034 Background: CD133 antigen is a specific surface marker for circulating endothelial progenitor cells (CEPs), pivotal in post-natal angiogenesis. We hypothesize that changes in levels of the CD133 mRNA expression and vascular endothelial growth factor (VEGF) may correlate with tumor response. Methods: After informed consent, we obtained 48 peripheral blood samples from patients with metastatic sarcoma including gastrointestinal stroma tumors (GIST). There were 16-paired samples before and after treatment including chemotherapy, or surgery, or imatinib. Of 24 patients with metastatic GIST enrolled, seven were paired samples. We measured CD133 mRNA levels by method (Lin E et al AACR 2003# 5392) and VEGF levels by ELISA (Genzyme, MA). The measurements were done in duplicates in two experiments. Results: The mean CD133 levels and VEGF levels before and after treatment was in Table 1 . The treatment resulted in significant reduction of CD133 mRNA expression (p = 0.035) as well as the level of VEGF (p = 0.014). Three patients experienced increase in CD133 expression had progressive disease. Among the paired GIST patients, there was a trend of increased CD133 mRNA expression levels in patients with progressive disease, death, or tumor recurrence. CD133 mRNA levels appeared elevated among the imatinib naïve patients and imatinib appeared to reset CD133 mRNA levels among the responding GIST patients to that of healthy volunteers. Conclusion: CD133 mRNA expression levels in sarcoma patients measured by real time-PCR assay appeared to correlate with tumor response. Unpublished independent work with NASBA assay platform in other solid tumors supported our findings ( www.primagen.com ). Further work is needed to reduce assay variability, and to determine the sensitivity and specificity of assay comparing to flow cytometry and to test assay’s applicability in the antiangiogenic therapy of cancer and the angiogenic therapy of cardiovascular diseases. [Table: see text] No significant financial relationships to disclose.
Post-transplant obesity impacts long-term survival after liver transplantation
Authors: Jeffrey van Son, Suzanne P. Stam, Antonio W. Gomes-Neto, Maryse C.J. Osté, Hans Blokzijl, Aad P. van den Berg, Robert J. Porte, Stephan J.L. Bakker, Vincent E. de Meijer
Journal: Metabolism (2020)

BackgroundShort-term survival after orthotopic liver transplantation (OLT) has improved over the past decades, but long-term survival remains impaired. The effects of obesity on long-term survival after OLT are controversial. Because pre-transplant body mass index (BMI) can be confounded by ascites, we hypothesized that post-transplant BMI at 1 year could predict long-term survival.MethodsA post-hoc analysis was performed of an observational cohort study consisting of adult recipients of a first OLT between 1993 and 2010. Baseline BMI was measured at 1-year post-transplantation to represent a stable condition. Recipients were stratified into normal weight (BMI < 25 kg/m2), overweight (25 ≤ BMI ≤ 30 kg/m2), and obese (BMI > 30 kg/m2). Kaplan-Meier survival analyses were performed with log-rank testing, followed by multivariable Cox proportional hazards regression analysis.ResultsOut of 370 included recipients, 184 had normal weight, 136 were overweight, and 50 were obese at 1-year post-transplantation. After median follow-up for 12.3 years, 107 recipients had died, of whom 46 (25%) had normal weight, 39 (29%) were overweight, and 22 (44%) were obese (log-rank P = 0.020). Obese recipients had a significantly increased mortality risk compared to normal weight recipients (HR 2.00, 95% CI 1.08–3.68, P = 0.027). BMI was inversely associated with 15 years patient survival (HR 1.08, 95% CI 1.03–1.14, P = 0.001 per kg/m2), independent of age, gender, muscle mass, transplant characteristics, cardiovascular risk factors, kidney- and liver function.ConclusionObesity at 1-year post-transplantation conveys a 2-fold increased mortality risk, which may offer potential for interventional strategies (i.e. dietary advice, lifestyle modification, or bariatric surgery) to improve long-term survival after OLT.
Clinicopathological correlation (CC) and outcome of breast cancer patients (pts) with resected brain metastasis (BM)
Authors: N. K. Ibrahim, G. Nguyen, D. Suki, B. Hennessy, A. Montero, J. E. Sarriera, F. Symmans, V. Valero, R. Sawaya, K. Aldape
Journal: Journal of Clinical Oncology (2006)

656 Background: We aimed at determining the pathologic features of metastatic breast lesions to the brain, and their correlation with the primary tumor, and their effect on postneurosurgical survival (PNS). Methods: Tissue samples from 123 pts who underwent surgical resection of BM at MDACC between 1984–2004, were examined for estrogen receptor-α (ER) by IHC and HER2 by FISH or IHC. Pts’ medical records were retrospectively reviewed for CC. Results: Median (med) age at BM diagnosis was 51 years. The med time from primary diagnosis to BM was 33 months (Range (R)0–304). Infiltrating ductal cancers were found in 89%. ER was negative and HER2 amplified in 73% and 37% of BM, respectively; ER-/Her2- was seen in 43%, ER-/Her2+ in 30%, ER+/Her2+ in 6%. Concordance of ER and HER2 status between primary and BM were both 88% (p=NS, for discordance). ER positivity was associated with a longer primary diagnosis to BM interval [med 39 months (R, 0–213) vs. 29 months (R, 0–304) in the ER- pts; p=0.02]; HER2 amplification was not (p=0.82). The med PNS was 11.2 months (R, 9.0–13.5) for 112 pts with no pre- craniotomy brain radiation. Pts with ER+ metastases experienced apparent longer PNS survival than ER- pts [med 18.9 months (95% CI, 4.8–33.1) vs. 9.9 months (95% CI, 7.6–12.1 months), respectively, p=0.06], as did those with HER2-amplified BM [med 13.8 months vs. 9.9 months, respectively; p=0.10]. Pts aged 45 to &lt;60 years had significantly longer pns survival (med 15.5 months) than younger or older pts (med 9.5 and 5.1 months, respectively), p≤.05 for all pair- wise comparisons. In mutivariate analyses correcting for age, functional status, and systemic tumor burden, neither ER nor HER2 status were independent predictors of pns. Of the 38 patients with HER2-amplified tumors and no pre- craniotomy radiation, 14 received trastuzumab (Tz) prior to initial neurosurgery. These 14 pts had longer PNS compared to those with HER2-amplified tumors not receiving Tz [median, 25.4 months vs. 10.7 months, respectively, p=NS). Conclusions: ER and HER2 positivity were highly concordant between primary and BM. Resected BM were more likely to be ER- or HER2-amplified. ER positivity and HER2 amplification were not significant independent predictors of PNS, though both showed a strong trend in univariate analyses. Middle age group pts had the best PNS survival. No significant financial relationships to disclose.